• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

TerSera touts study results of infusion reaction prevention treatment

March 5, 2021 By Sean Whooley

TerSera TherapeuticsTerSera Therapeutics today announced the presentation of positive data from its study of preventing hypersensitivity infusion reactions.

Deerfield, Ill.-based TerSera’s intravenous (IV) cetirizine injection was pitted against IV diphenhydramine in preventing hypersensitivity infusion reactions in patients with breast cancer and other malignancies, according to a news release.

The randomized, double-blind Phase 2 study evaluated TerSera’s cetirizine hydrochloride injection against IV diphenhydramine in 34 patients receiving paclitaxel or anti-CD20 Ab (rituximab, its biosimilar or obinutuzumab). In TerSera’s treatment group, the number of patients with infusion reactions was 2 of 17, versus 3 of 17 in the other group.

Time for discharge in TerSera’s treatment group was 24 minutes less than the other treatment, while treatment-related adverse events totaled three with IV cetirizine and six with IV diphenhydramine.

Patients in the TerSera group were treated with Quzyttir, the first and only injectable second-generation H1 antihistamine approved by the FDA for treating acute urticaria in adults and children six months of age and older. It is not yet approved for the prevention of infusion reactions.

“We are pleased with the results of this Phase 2 study,” TerSera EVP of R&D & CMO Dr. Nancy Joseph-Ridge said in the release. “This is the first study of IV cetirizine compared to IV diphenhydramine for the prevention of infusion reactions, an investigational use of IV cetirizine.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals Tagged With: TerSera Therapeutics

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS